Biotech News

NuCana Compliant with All Nasdaq Continued Listing Criteria

NuCana plc (NCNA)NuCana plcCompany update

Anticipated Cash Runway into 2029 EDINBURGH, United Kingdom, Sept. 05, 2025 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) (“NuCana” or the “Company”) announced that it has received formal notification from The Nasdaq Stock Market on September 4, 2025 confirming that the Company is in compliance

Related news

NuCana plc

ProTide Oncology Company NuCana applies its ProTide chemistry platform to transform nucleoside analogs into medicines designed to generate higher concentrations of active anticancer metabolites inside tumor cells. NUC-7738 NUC-7738 is a ProTide that disrupts RNA polyadenylation and affects multiple components of the tumor...

Recent company news

Stock data

Close
1.52 USD
Market cap
8.62M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States